Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04190706
Other study ID # 69HCL18_0097
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 21, 2020
Est. completion date May 17, 2022

Study information

Verified date March 2023
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to evaluate the synergistic effects of daily consumption of food products fortified with bioactive components (fibres, polyphenols, omega-3, Slow Digestible Starch) for 9 weeks, compared to the daily intake of standard food products on low-grade inflammation in cardiometabolic risk subject. The inflammatory parameters will be assessed in fasting and in postprandial period after the consumption of a hyper-carbohydrate and hyper-lipidic test meal called Flexmeal. A metabolic stress will be induced by a fructose ingestion challenge during the last 6 days of interventional period.


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date May 17, 2022
Est. primary completion date May 17, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 65 Years
Eligibility Inclusion Criteria: - Healthy men and women - Body Mass Index of 25 to 35 kg/m2 - Waist circumference greater than 80 cm for women and than 96 cm for men - Daily biscuits consumption - Fibers intake <25g/day Exclusion Criteria: - Medical history of digestive surgery or disease - Large polyphenols food products consumer (cranberries, red berries, coffee, tea, red wine, fruits and vegetables…) - Current or recent (<12 weeks) intake of antibiotics or gastro-intestinal medicinal product - Current probiotics, prebiotics, fibers complement, and/or any products modulation gut transit - Feeding particular diet such as vegetarian diet or hyperprotein diet - Current weight loss diet - Pregnant or lactating woman or woman who did not use effective contraception - Drinking more than 3 glasses of alcohol per day (>30g/day) - Smoking more than 5 cigarettes per day

Study Design


Intervention

Other:
bioactive components fortified food products intake (biscuits and cookies)
Volunteers will have to consume daily 100 g of fortified biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)
control food products intake (biscuits and cookies)
Volunteers will have to consume daily 100 g of standard biscuits and cookies instead of those usually consumed during nine weeks. The last week, volunteers will have to consume daily a fructose solution (3g/kg fat free mass)

Locations

Country Name City State
France Centre de Recherche en Nutrition Humaine Rhône-Alpes Pierre-Bénite

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline postprandial plasma endotoxemia binding protein kinetics: LBP (lipopolysaccharide-binding protein) and CD14 (Cluster of differentiation 14) LBP and CD14 proteins will be measured at time 0, 120 and 300 after test meal intake baseline, 8 and 9 weeks
Secondary Change from baseline fasting and postprandial plasma inflammatory markers: MCP-1, RANTES, IFN?, IL-6, TNF-a, IL-1ß, CRPus, adiponectin MCP-1 ( monocyte chemotactic protein-1), RANTES (Regulated on activation, normal T expressed and secreted), IFN? (Interferon ?) , IL-6 (Interleukin 6), TNF-a (Tumor Necrosis Factor a), IL-1ß (Interleukin 1ß), CRPus, adiponectin will be measured at time 0 and 300 minutes after test meal intake baseline, 8 and 9 weeks
Secondary Change of fasting and postprandial plasma inflammatory endotoxemia LPS (lipopolysaccharide) LPS will be measured at time 0, 60, 120, 180, 240, 300 after test meal intake baseline, 8 and 9 weeks
Secondary Change from baseline fasting and postprandial plasma endothelial function markers: Human CVD Panel 2, Lipocalin-2/NGAL, Myeloperoxidase, sICAM-1, sVCAM-1, ADAMTS13, D-dimer, GDF-15, Myoglobin, sP-Selectin, Serum Amyloid A Human CVD Panel 2, Lipocalin-2/NGAL (neutrophil gelatinase-associated lipocalin), Myeloperoxidase, sICAM-1(Soluble Inter-cellular Adhesion Molecule-1), sVCAM-1(Soluble Form of Vascular Cell Adhesion Molecule 1), ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), D-dimer, GDF-15 (Growth differentiation factor 15), Myoglobin, sP-Selectin, Serum Amyloid A will be measured at time 0 and 300 minutes after test meal intake baseline, 8 and 9 weeks
Secondary Change from baseline fasting plasma oxidative stress parameters: GSH, GSSG, Glutathion peroxidase/ reductase activity, MDA GSH (glutathione), GSSG (glutathione disulfide), Glutathion peroxidase/ reductase activity will be measured at time 0 and MDA (malondialdehyde) will be measured at 0 and 300 minutes after test meal intake baseline, 8 and 9 weeks
Secondary Change from baseline body composition Body composition will be measured by BodPod technique baseline, 8 and 9 weeks
Secondary Change from baseline plasma metabolites and hormone kinetics : glucose, insulin, triglycerides, non-esterified fatty acids Plasma metabolites and hormone will be measured at time -30, 0, 15, 30, 45, 60, 90, 120, 180, 240, 300 minutes after test meal intake baseline, 8 and 9 weeks
Secondary Change from baseline fasting plasma lipids : total cholesterol , HDL cholesterol, LDL cholesterol, triglycerides, non-esterified fatty acids fasting plasma lipids will be measured before test meal ingestion baseline, 8 and 9 weeks
Secondary Change from baseline resting energy expenditure resting metabolic rate will be measured by indirect calorimetry baseline, 8 and 9 weeks
Secondary Change from baseline substrates oxidation substrates oxidation will be measured by indirect calorimetry after test meal intake during five hours. baseline, 8 and 9 weeks
Secondary Change from baseline gut microbiota composition gut microbiota composition will be measured by 16S RNA (ribonucleic acid) analysis baseline, 8 weeks
Secondary Change from baseline stool consistency stool consistency will be measured by Bristol scale and every week during the interventional period nine weeks
Secondary Change from baseline stool frequency stool frequency will be measured by questionnaire at baseline and every week during the interventional period nine weeks
Secondary Change from baseline tolerance gastro-intestinal symptoms like bloating ,abdominal rumbling ,flatulence ,abdominal pain, nausea, vomiting Gastro intestinal symptoms will be collected by questionnaires and visual analogue scale (VAS) score (on a 90mm horizontal line; from no symptom (minimal) to serious symptom (maximum)) at baseline and every week during the interventional period nine weeks
Secondary Change from baseline diet intake diet intake will be evaluated by a three days diet survey baseline, 8 and 9 weeks
Secondary Change from baseline fasting plasma zonulin comparison of fasting plasma zonulin from baseline baseline, 8 and 9 weeks
Secondary Change from baseline polyphenols urinary concentrations Comparison of polyphenols urinary concentrations from baseline baseline, 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04940962 - Translational Study Using Human Abdominal Adipose Tissue Biopsies to Investigate the Role of Cannabinoid Receptor 1 (CB1) in Controlling Endocannabinoid and Adipokine Secretion N/A
Completed NCT02194504 - The Belly Fat Study: Nutritional Intervention to Improve Metabolic Health in Subjects With Increased Abdominal Adiposity N/A
Completed NCT00374218 - Effect of Replacing HFCS With Sucromalt in Subjects With Raised Waist Circumference Phase 2
Completed NCT00520858 - Effects of Exercise Modality on Abdominal Obesity and Health Risk Factors in Older Men and Women N/A
Recruiting NCT03212391 - WAVE Study- Walking and Aging in VErona Study N/A
Completed NCT03898518 - The Effects of a Jump Rope Exercise Program on Body Composition and Self-efficacy in Obese Adolescent Girls N/A
Recruiting NCT04136717 - Influence of FreeO2 on Percentage of Time Within Oxygen Saturation Target Using Noninvasive Ventilation (NIV) and Continuous Positive Airway Pressure (CPAP) for Patients Admitted for AECOPD or Bariatric Surgery N/A
Completed NCT05413954 - To Evaluate the Health Effect of Particular Fatty Acids Profiles From Eggs N/A
Recruiting NCT05062954 - Effects of a Polyphenol-rich Cranberry Extract on Cardiometabolic and Neurocognitive Health N/A
Completed NCT01472666 - Dairy Lipids, Proteins, and the Metabolic Syndrome - "DairyHealth" N/A
Completed NCT00990457 - Evaluating the Effects Two Diets Combined With Exercise in Persons With Abdominal Obesity (The SHAPE5 Study) Phase 3
Completed NCT05685017 - Adiponectin, ICAM-1, VCAM-1 Levels and Metabolic Syndrome in Obese Adolescents
Completed NCT03773900 - Characterization of Gut Microbiota Composition and Activity After a Daily Supplementation of 4.5 g/Day of ChitinGlucan Fibre During 3 Weeks in At-cardiometabolic Risk Volunteers N/A
Completed NCT04635332 - Food Literacy and Physical Activity Intervention to Optimize Metabolic Health Among Women in Urban Uganda N/A
Completed NCT00739180 - Physical Activity in Youth: Implications for Reversing Risk Factors for Type 2 Diabetes N/A
Completed NCT00664729 - Diet, Exercise, Metabolism, and Obesity in Older Women N/A
Completed NCT03389425 - Application of the SIMPLE Program for Weight Loss at Pathways to Housing: A Feasibility Study N/A
Completed NCT05900843 - Weight Abnormalities With Diet and Exercise Frequency in Egyptian Children With Cerebral Palsy
Not yet recruiting NCT06376955 - High Intensity Interval Versus Focused Ultrasound on Insulin Resistance in Diabetics With Abdominal Obesity N/A
Recruiting NCT05879692 - Response of Irritable Bowel Syndrome to Abdominal Fat Reduction N/A